Framingham Risk Score Prediction at 12 Months in the STANDFIRM Randomized Control Trial.

Journal: Journal of the American Heart Association
Published Date:

Abstract

BACKGROUND: The STANDFIRM (Shared Team Approach Between Nurses and Doctors for Improved Risk Factor Management; ANZCTR registration ACTRN12608000166370) trial was designed to test the effectiveness of chronic disease care management for modifying the Framingham risk score (FRS) among patients with stroke or transient ischemic attack. The primary outcome of change in FRS was not met. We determine baseline characteristics that predict reduction in FRS at 12 months and whether future FRS is predetermined at baseline.

Authors

  • Thanh G Phan
    Department of Neurology Monash Medical Centre Melbourne Australia.
  • Velandai K Srikanth
    National Centre for Healthy Ageing, Frankston, Victoria, Australia.
  • Dominique A Cadilhac
    Stroke and Aging Research Group, Department of Medicine School of Clinical Sciences at Monash Health, Monash University Melbourne Australia.
  • Mark Nelson
    Menzies Institute for Medical Research, University of Tasmania Hobart Australia.
  • Joosup Kim
    Stroke and Aging Research Group, Department of Medicine School of Clinical Sciences at Monash Health, Monash University Melbourne Australia.
  • Muideen T Olaiya
    Stroke and Aging Research Group, Department of Medicine School of Clinical Sciences at Monash Health, Monash University Melbourne Australia.
  • Sharyn M Fitzgerald
    School of Public Health and Preventive Medicine Monash University Melbourne Australia.
  • Christopher Bladin
    Victorian Stroke Telemedicine Ambulance Victoria Melbourne Victoria Australia.
  • Richard Gerraty
    Department of Medicine Epworth Healthcare Richmond Victoria Australia.
  • Henry Ma
    Department of Neurology Monash Medical Centre Melbourne Australia.
  • Amanda G Thrift
    Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.